title: Tropomyosin dephosphorylation results in compensated cardiac hypertrophy.
abstract: Phosphorylation of tropomyosin (Tm) has been shown to vary in mouse models of cardiac hypertrophy. Little is known about the in vivo role of Tm phosphorylation. This study examines the consequences of Tm dephosphorylation in the murine heart. Transgenic (TG) mice were generated with cardiac specific expression of α-Tm with serine 283, the phosphorylation site of Tm, mutated to alanine. Echocardiographic analysis and cardiomyocyte cross-sectional area measurements show that α-Tm S283A TG mice exhibit a hypertrophic phenotype at basal levels. Interestingly, there are no alterations in cardiac function, myofilament calcium (Ca(2+)) sensitivity, cooperativity, or response to β-adrenergic stimulus. Studies of Ca(2+) handling proteins show significant increases in sarcoplasmic reticulum ATPase (SERCA2a) protein expression and an increase in phospholamban phosphorylation at serine 16, similar to hearts under exercise training. Compared with controls, the decrease in phosphorylation of α-Tm results in greater functional defects in TG animals stressed by transaortic constriction to induce pressure overload-hypertrophy. This is the first study to investigate the in vivo role of Tm dephosphorylation under both normal and cardiac stress conditions, documenting a role for Tm dephosphorylation in the maintenance of a compensated or physiological phenotype. Collectively, these results suggest that modification of the Tm phosphorylation status in the heart, depending upon the cardiac state/condition, may modulate the development of cardiac hypertrophy.
authors.affiliation: Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.
authors.forename: Emily M
authors.initials: EM
authors.lastname: Schulz
authors.forename: Richard N
authors.initials: RN
authors.lastname: Correll
authors.forename: Hajer N
authors.initials: HN
authors.lastname: Sheikh
authors.forename: Marco S
authors.initials: MS
authors.lastname: Lofrano-Alves
authors.forename: Patti L
authors.initials: PL
authors.lastname: Engel
authors.forename: Gilbert
authors.initials: G
authors.lastname: Newman
authors.forename: Jo El J
authors.initials: Jel J
authors.lastname: Schultz
authors.forename: Jeffery D
authors.initials: JD
authors.lastname: Molkentin
authors.forename: Beata M
authors.initials: BM
authors.lastname: Wolska
authors.forename: R John
authors.initials: RJ
authors.lastname: Solaro
authors.forename: David F
authors.initials: DF
authors.lastname: Wieczorek
mesh_terms: D000818:Animals; D002118:Calcium / Q000378:metabolism; D006332:Cardiomegaly / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D005260:Female; D006321:Heart / Q000503:physiopathology; D006801:Humans; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009206:Myocardium / Q000378:metabolism; D010766:Phosphorylation; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000235:genetics / Q000378:metabolism; D014335:Tropomyosin / Q000235:genetics / Q000378:metabolism*
chemical_list: D014335:Tropomyosin; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; C506947:Atp2a2 protein, mouse; D002118:Calcium